Ginkgo Bioworks Holdings (DNA) EPS (Weighted Average and Diluted) (2020 - 2025)
Ginkgo Bioworks Holdings filings provide 6 years of EPS (Weighted Average and Diluted) readings, the most recent being -$1.42 for Q4 2025.
- On a quarterly basis, EPS (Weighted Average and Diluted) rose 27.55% to -$1.42 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.65, a 46.65% increase, with the full-year FY2025 number at -$5.64, up 46.49% from a year prior.
- EPS (Weighted Average and Diluted) hit -$1.42 in Q4 2025 for Ginkgo Bioworks Holdings, up from -$1.45 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.04 in Q2 2021 to a low of -$49.01 in Q4 2022.
- Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.21 (2021), compared with a mean of -$4.13.
- Biggest five-year swings in EPS (Weighted Average and Diluted): surged 91.27% in 2023 and later plummeted 4600.0% in 2024.
- Ginkgo Bioworks Holdings' EPS (Weighted Average and Diluted) stood at -$1.21 in 2021, then crashed by 3950.41% to -$49.01 in 2022, then surged by 91.27% to -$4.28 in 2023, then skyrocketed by 54.21% to -$1.96 in 2024, then grew by 27.55% to -$1.42 in 2025.
- The last three reported values for EPS (Weighted Average and Diluted) were -$1.42 (Q4 2025), -$1.45 (Q3 2025), and -$1.1 (Q2 2025) per Business Quant data.